<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Negat Results Biomed</journal-id><journal-title>Journal of Negative Results in Biomedicine</journal-title><issn pub-type="epub">1477-5751</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16965635</article-id><article-id pub-id-type="pmc">1578582</article-id><article-id pub-id-type="publisher-id">1477-5751-5-14</article-id><article-id pub-id-type="doi">10.1186/1477-5751-5-14</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Role of metabolically active hormones in the insulin resistance associated with short-term glucocorticoid treatment</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Patel</surname><given-names>Jeetesh V</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Jeetesh.patel@swbh.nhs.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Cummings</surname><given-names>David E</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>davidec@washington.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Girod</surname><given-names>John P</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>girodjp@upmc.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Mascarenhas</surname><given-names>Alwin V</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>alwin_vm@yahoo.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Hughes</surname><given-names>Elizabeth A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>elizabeth.hughes@swbh.nhs.uk</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Gupta</surname><given-names>Manjula</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>guptam@ccf.org</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Lip</surname><given-names>Gregory YH</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gregory.lip@swbh.nhs.uk</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Reddy</surname><given-names>Sethu</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>reddys@ccf.org</email></contrib><contrib id="A9" corresp="yes" contrib-type="author"><name><surname>Brotman</surname><given-names>Daniel J</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>brotman@jhmi.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine and Sandwell Medical Research Unit, Sandwell and West Birmingham Hospitals NHS Trust, West Midlands, UK</aff><aff id="I2"><label>2</label>Department of Medicine, University of Washington, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA</aff><aff id="I3"><label>3</label>Department of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA</aff><aff id="I4"><label>4</label>Departments of General Internal Medicine and Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, Cleveland, OH, USA</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>11</day><month>9</month><year>2006</year></pub-date><volume>5</volume><fpage>14</fpage><lpage>14</lpage><ext-link ext-link-type="uri" xlink:href="http://www.jnrbm.com/content/5/1/14"></ext-link><history><date date-type="received"><day>30</day><month>5</month><year>2006</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 Patel et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Patel et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="4573" xml_f="4583" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4594" xml_f="5014" txt_i="22" txt_f="442">The mechanisms by which glucocorticoid therapy promotes obesity and insulin resistance are incompletely characterized. Modulations of the metabolically active hormones, tumour necrosis factor alpha (TNF alpha), ghrelin, leptin and adiponectin are all implicated in the development of these cardiovascular risk factors. Little is known about the effects of short-term glucocorticoid treatment on levels of these hormones.</offsets></p></sec><sec><title><offsets xml_i="5036" xml_f="5067" txt_i="444" txt_f="475">Research methods and procedures</offsets></title><p><offsets xml_i="5078" xml_f="5364" txt_i="476" txt_f="762">Using a blinded, placebo-controlled approach, we randomised 25 healthy men (mean (SD) age: 24.2 (5.4) years) to 5 days of treatment with either placebo or oral dexamethasone 3 mg twice daily. Fasting plasma TNFα, ghrelin, leptin and adiponectin were measured before and after treatment.</offsets></p></sec><sec><title><offsets xml_i="5386" xml_f="5393" txt_i="764" txt_f="771">Results</offsets></title><p><offsets xml_i="5404" xml_f="5715" txt_i="772" txt_f="1083">Mean changes in all hormones were no different between treatment arms, despite dexamethasone-related increases in body weight, blood pressure, HDL cholesterol and insulin. Changes in calculated indices of insulin sensitivity (HOMA-S, insulin sensitivity index) were strongly related to dexamethasone treatment (</offsets><italic><offsets xml_i="5723" xml_f="5725" txt_i="1083" txt_f="1085">p </offsets></italic><offsets xml_i="5734" xml_f="5746" txt_i="1085" txt_f="1094">&lt; 0.001).</offsets></p></sec><sec><title><offsets xml_i="5768" xml_f="5778" txt_i="1096" txt_f="1106">Discussion</offsets></title><p><offsets xml_i="5789" xml_f="5944" txt_i="1107" txt_f="1262">Our data do not support a role for TNF alpha, ghrelin, leptin or adiponectin in the insulin resistance associated with short-term glucocorticoid treatment.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="6006" xml_f="6016" txt_i="1271" txt_f="1281">Background</offsets></title><p><offsets xml_i="6027" xml_f="6151" txt_i="1282" txt_f="1406">Glucocorticoids are common therapy for inflammatory conditions, but they generate a diverse array of unwanted side effects [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6182" xml_f="6183" txt_i="1406" txt_f="1407">1</offsets></xref><offsets xml_i="6190" xml_f="6377" txt_i="1407" txt_f="1594">]. Their mechanisms of action involve the activation of transcription factors that interact with a battery of responsive genes, stimulating inflammatory and immuno-regulatory cross-talk [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6408" xml_f="6409" txt_i="1594" txt_f="1595">2</offsets></xref><offsets xml_i="6416" xml_f="6476" txt_i="1595" txt_f="1655">]. Glucocorticoid therapy promotes both insulin resistance [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6507" xml_f="6508" txt_i="1655" txt_f="1656">3</offsets></xref><offsets xml_i="6515" xml_f="6516" txt_i="1656" txt_f="1657">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6547" xml_f="6548" txt_i="1657" txt_f="1658">4</offsets></xref><offsets xml_i="6555" xml_f="6578" txt_i="1658" txt_f="1681">] and central obesity [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6609" xml_f="6610" txt_i="1681" txt_f="1682">5</offsets></xref><offsets xml_i="6617" xml_f="6654" txt_i="1682" txt_f="1719">], perpetuating cardiovascular risk [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="6685" xml_f="6686" txt_i="1719" txt_f="1720">6</offsets></xref><offsets xml_i="6693" xml_f="7167" txt_i="1720" txt_f="2194">]. However, the mechanisms of glucocorticoid-mediated obesity remain incompletely characterized, and the impact of glucocorticoids on hormones and cytokines that regulate hunger, satiety and adiposity remain unclear. Therefore, we sought to determine the acute effects of glucocorticoid administration on tumor necrosis factor – alpha (TNF alpha), ghrelin, leptin, and adiponectin–all hormones and cytokines thought to play an important role in the regulation of adiposity [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="7198" xml_f="7199" txt_i="2194" txt_f="2195">7</offsets></xref><offsets xml_i="7206" xml_f="7208" txt_i="2195" txt_f="2197">].</offsets></p><p><offsets xml_i="7215" xml_f="7412" txt_i="2198" txt_f="2395">TNF alpha represents a potential link between adiposity and insulin resistance, since circulating levels are associated with adipose mass and exogenous administration increases insulin resistance [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7443" xml_f="7444" txt_i="2395" txt_f="2396">8</offsets></xref><offsets xml_i="7451" xml_f="7681" txt_i="2396" txt_f="2626">]. Ghrelin, an orexigenic gut peptide, is implicated in long- and short-term body weight regulation. Exogenous administration blocks insulin action, both via indirect effects on other hormones and via direct actions in the liver [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="7712" xml_f="7713" txt_i="2626" txt_f="2627">9</offsets></xref><offsets xml_i="7720" xml_f="7871" txt_i="2627" txt_f="2778">]. Leptin is an adipocyte-derived hormone that circulates in proportion to body fat stores; it promotes weight loss and increases insulin sensitivity [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="7903" xml_f="7905" txt_i="2778" txt_f="2780">10</offsets></xref><offsets xml_i="7912" xml_f="8014" txt_i="2780" txt_f="2882">]. Adiponectin, also from adipose tissue, increases insulin sensitivity and can decrease body weight [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="8046" xml_f="8048" txt_i="2882" txt_f="2884">11</offsets></xref><offsets xml_i="8055" xml_f="8469" txt_i="2884" txt_f="3298">]. We hypothesised that short-term glucocorticoid treatment among healthy individuals would cause insulin resistance, with coordinated increases in TNF alpha, leptin and ghrelin, and decreases in adiponectin. For this study, we used a synthetic glucocorticoid, dexamethasone, which selectively targets the glucocorticoid receptor and glucocorticoid responsive genes, without significant mineralocorticoid effects [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="8500" xml_f="8501" txt_i="3298" txt_f="3299">1</offsets></xref><offsets xml_i="8508" xml_f="8510" txt_i="3299" txt_f="3301">].</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="8551" xml_f="8558" txt_i="3303" txt_f="3310">Methods</offsets></title><p><offsets xml_i="8569" xml_f="8757" txt_i="3311" txt_f="3499">Weperformed a randomized, double-blind, placebo-controlled study in healthy young men ages 19–39 who were recruited by local advertisements. The methods are described in detail elsewhere [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="8789" xml_f="8791" txt_i="3499" txt_f="3501">12</offsets></xref><offsets xml_i="8798" xml_f="9958" txt_i="3501" txt_f="4661">]. Briefly, subjects were treated with dexamethasone 3 mg twice daily for 5 days or with placebo. Fasting 8 AM blood samples were obtained before and after the intervention. Potential subjects were excluded if they had any of the following: ongoing medical or psychiatric illnesses, regular use of prescription or non-prescription medications, illicit drug use or excessive alcohol use, surgery or hospitalization in the preceding 3 months, exposure to exogenous glucocorticoids in the preceding year, or non-traditional sleep/wake habits (e.g.: night shift work, frequent travel across time zones). Subjects were advised to maintain their usual sleep-wake schedule, exercise and dietary habits during the study, and were advised not to take any prescription medications, over-the-counter medications, or alcohol during the protocol. All subjects provided written informed consent. Investigators and subjects were blinded to treatment assignment, and compliance was confirmed by measuring post-treatment cortisol levels (undetectable in all subjects who received dexamethasone). The Cleveland Clinic Foundation Institutional Review Board approved the protocol.</offsets></p><sec><title><offsets xml_i="9974" xml_f="9989" txt_i="4662" txt_f="4677">Laboratory data</offsets></title><p><offsets xml_i="10000" xml_f="10558" txt_i="4678" txt_f="5232">Separated serum and EDTA plasma were stored at -70°C for batch analysis. Serum levels of glucose, cholesterol and triglycerides were determined using routine autoanalyser assays. Insulin levels were determined using an enzyme immunoassay (AIA NexIA, Tosoh Bioscience, S. San Francisco, CA). TNFα, leptin and adiponectin levels were measured by enzyme linked immunosorbant assay (ELISA) in plasma, using commercially available antibodies (R&amp;D Systems, Abingdon, UK). Plasma ghrelin was measured by radio-immunoassay (Phoenix Pharmaceuticals, Belmont, CA).</offsets></p><p><offsets xml_i="10565" xml_f="10701" txt_i="5233" txt_f="5369">Insulin sensitivity was assessed using the homeostatic model (HOMA-S), which is directly related to fasting insulin and glucose levels [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="10733" xml_f="10735" txt_i="5369" txt_f="5371">13</offsets></xref><offsets xml_i="10742" xml_f="10806" txt_i="5371" txt_f="5435">]. A weighted combination of fasting insulin and triglycerides [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="10838" xml_f="10840" txt_i="5435" txt_f="5437">14</offsets></xref><offsets xml_i="10847" xml_f="10944" txt_i="5437" txt_f="5534">], 'insulin sensitivity index' (ISI), was also used as surrogate a marker of insulin sensitivity.</offsets></p></sec><sec><title><offsets xml_i="10966" xml_f="11008" txt_i="5536" txt_f="5578">Power calculation and statistical analysis</offsets></title><p><offsets xml_i="11019" xml_f="11125" txt_i="5579" txt_f="5685">We hypothesised that dexamethasone treatment would significantly decrease HOMA-S. Based on previous data [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="11156" xml_f="11157" txt_i="5685" txt_f="5686">3</offsets></xref><offsets xml_i="11164" xml_f="11165" txt_i="5686" txt_f="5687">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="11197" xml_f="11199" txt_i="5687" txt_f="5689">14</offsets></xref><offsets xml_i="11206" xml_f="11816" txt_i="5689" txt_f="6296">], 12 patients would be sufficient to observe a significant (p &lt; 0.05) decrease of at least 1.9 in HOMA-S using a two-sided test at 80% power. The change from baseline to post-intervention was calculated in each variable (variables with highly skewed distributions were log-transformed prior to this). Data were analysed using parametric and non-parametric tests, with ANOVA and multiple linear and logistic regression analyses as appropriate (SPSS Inc., Chicago, IL). Partial correlation analysis (two-tailed) was used to adjust the effects of treatment arm, used for bivariate analysis among all subjects.</offsets></p></sec></sec><sec><title><offsets xml_i="11844" xml_f="11851" txt_i="6299" txt_f="6306">Results</offsets></title><p><offsets xml_i="11862" xml_f="12111" txt_i="6307" txt_f="6556">Of the 25 male subjects (24.2 (5.4) years), 13 were randomized to dexamethasone and 12 to placebo. Baseline plasma TNFα, ghrelin, leptin and adiponectin were comparable among subjects in the dexamethasone and placebo groups before intervention (all </offsets><italic><offsets xml_i="12119" xml_f="12121" txt_i="6556" txt_f="6558">P </offsets></italic><offsets xml_i="12130" xml_f="12211" txt_i="6558" txt_f="6636">&gt; 0.15), and these values did not change significantly after treatment (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="12243" xml_f="12244" txt_i="6636" txt_f="6637">1</offsets></xref><offsets xml_i="12251" xml_f="12501" txt_i="6637" txt_f="6887">). In contrast, there were significant increases in body-mass index (BMI), systolic blood pressure, HDL cholesterol, serum insulin and insulin resistance amongst subjects on glucocorticoid therapy compared with those on placebo (described elsewhere [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="12533" xml_f="12535" txt_i="6887" txt_f="6889">12</offsets></xref><offsets xml_i="12542" xml_f="12950" txt_i="6889" txt_f="7297">]). All subjects treated with dexamethasone had undetectable post-treatment morning cortisol levels, confirming compliance with the intervention. Mean changes (pre-treatment value minus post-treatment value) in TNFα, leptin and adiponectin were not significantly correlated with changes in cardiovascular risk factors, but there was a modest association between changes ghrelin and diastolic blood pressure (</offsets><italic><offsets xml_i="12958" xml_f="12960" txt_i="7297" txt_f="7299">P </offsets></italic><offsets xml_i="12969" xml_f="13012" txt_i="7299" txt_f="7342">= 0.04), after adjusting for treatment arm.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="13060" xml_f="13067" txt_i="7343" txt_f="7350">Table 1</offsets></label><caption><p><offsets xml_i="13087" xml_f="13245" txt_i="7350" txt_f="7508">Plasma levels of TNF alpha, ghrelin, leptin and adiponectin among healthy male volunteers during short-term intervention with either dexamethasone or placebo.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="13324" xml_f="13375" txt_i="7509" txt_f="7560">Circulating levels of metabolically active hormones</offsets></td><td align="left" colspan="2"><offsets xml_i="13409" xml_f="13422" txt_i="7561" txt_f="7574">Pre-treatment</offsets></td><td align="left" colspan="2"><offsets xml_i="13456" xml_f="13470" txt_i="7575" txt_f="7589">Post-treatment</offsets></td><td align="left"><offsets xml_i="13492" xml_f="13586" txt_i="7590" txt_f="7684">Significance of the difference between changes (pre-post), Placebo vs. Dexamethasone (p-value)</offsets></td></tr><tr><td></td><td colspan="4"><hr></hr></td><td></td></tr><tr><td></td><td align="left"><offsets xml_i="13683" xml_f="13699" txt_i="7689" txt_f="7705">Placebo (n = 12)</offsets></td><td align="left"><offsets xml_i="13721" xml_f="13734" txt_i="7706" txt_f="7719">Dexamethasone</offsets><break></break><offsets xml_i="13749" xml_f="13757" txt_i="7719" txt_f="7727">(n = 13)</offsets></td><td align="left"><offsets xml_i="13779" xml_f="13786" txt_i="7728" txt_f="7735">Placebo</offsets><break></break><offsets xml_i="13801" xml_f="13809" txt_i="7735" txt_f="7743">(n = 12)</offsets></td><td align="left"><offsets xml_i="13831" xml_f="13844" txt_i="7744" txt_f="7757">Dexamethasone</offsets><break></break><offsets xml_i="13859" xml_f="13867" txt_i="7757" txt_f="7765">(n = 13)</offsets></td><td></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="13922" xml_f="13951" txt_i="7767" txt_f="7796">Insulin sensitivity (HOMA-S)*</offsets></td><td align="left"><offsets xml_i="13973" xml_f="13990" txt_i="7797" txt_f="7814">7.55 (6.885–8.85)</offsets></td><td align="left"><offsets xml_i="14012" xml_f="14028" txt_i="7815" txt_f="7831">8.28 (7.26–9.85)</offsets></td><td align="left"><offsets xml_i="14050" xml_f="14066" txt_i="7832" txt_f="7848">7.07 (6.03–9.96)</offsets></td><td align="left"><offsets xml_i="14088" xml_f="14104" txt_i="7849" txt_f="7865">5.46 (4.79–7.39)</offsets></td><td align="left"><offsets xml_i="14126" xml_f="14136" txt_i="7866" txt_f="7873">&lt; 0.001</offsets></td></tr><tr><td align="left"><offsets xml_i="14167" xml_f="14199" txt_i="7874" txt_f="7906">Insulin sensitivity index (ISI)*</offsets></td><td align="left"><offsets xml_i="14221" xml_f="14237" txt_i="7907" txt_f="7923">1.16 (0.81–1.58)</offsets></td><td align="left"><offsets xml_i="14259" xml_f="14275" txt_i="7924" txt_f="7940">1.35 (0.95–2.48)</offsets></td><td align="left"><offsets xml_i="14297" xml_f="14313" txt_i="7941" txt_f="7957">0.94 (0.53–2.46)</offsets></td><td align="left"><offsets xml_i="14335" xml_f="14351" txt_i="7958" txt_f="7974">0.38 (0.26–0.77)</offsets></td><td align="left"><offsets xml_i="14373" xml_f="14383" txt_i="7975" txt_f="7982">&lt; 0.001</offsets></td></tr><tr><td align="left"><offsets xml_i="14414" xml_f="14449" txt_i="7983" txt_f="8018">Tumor Necrosis Factor alpha (pg/ml)</offsets></td><td align="left"><offsets xml_i="14471" xml_f="14485" txt_i="8019" txt_f="8033">660 (230–1580)</offsets></td><td align="left"><offsets xml_i="14507" xml_f="14519" txt_i="8034" txt_f="8046">600 (0–1080)</offsets></td><td align="left"><offsets xml_i="14541" xml_f="14556" txt_i="8047" txt_f="8062">620 (240– 1460)</offsets></td><td align="left"><offsets xml_i="14578" xml_f="14590" txt_i="8063" txt_f="8075">580 (0–1080)</offsets></td><td align="left"><offsets xml_i="14612" xml_f="14616" txt_i="8076" txt_f="8080">0.68</offsets></td></tr><tr><td align="left"><offsets xml_i="14647" xml_f="14662" txt_i="8081" txt_f="8096">Ghrelin (pg/ml)</offsets></td><td align="left"><offsets xml_i="14684" xml_f="14697" txt_i="8097" txt_f="8110">422 (239–591)</offsets></td><td align="left"><offsets xml_i="14719" xml_f="14732" txt_i="8111" txt_f="8124">342 (285–497)</offsets></td><td align="left"><offsets xml_i="14754" xml_f="14767" txt_i="8125" txt_f="8138">359 (265–465)</offsets></td><td align="left"><offsets xml_i="14789" xml_f="14802" txt_i="8139" txt_f="8152">291 (188–347)</offsets></td><td align="left"><offsets xml_i="14824" xml_f="14828" txt_i="8153" txt_f="8157">0.19</offsets></td></tr><tr><td align="left"><offsets xml_i="14859" xml_f="14873" txt_i="8158" txt_f="8172">Leptin (pg/ml)</offsets></td><td align="left"><offsets xml_i="14895" xml_f="14916" txt_i="8173" txt_f="8194">14,400 (8,400–25,600)</offsets></td><td align="left"><offsets xml_i="14938" xml_f="14959" txt_i="8195" txt_f="8216">10,700 (4,200–19,800)</offsets></td><td align="left"><offsets xml_i="14981" xml_f="15002" txt_i="8217" txt_f="8238">17,800 (2,700–22,600)</offsets></td><td align="left"><offsets xml_i="15024" xml_f="15045" txt_i="8239" txt_f="8260">15,900 (4,200–30,500)</offsets></td><td align="left"><offsets xml_i="15067" xml_f="15071" txt_i="8261" txt_f="8265">0.85</offsets></td></tr><tr><td align="left"><offsets xml_i="15102" xml_f="15121" txt_i="8266" txt_f="8285">Adiponectin (ng/ml)</offsets></td><td align="left"><offsets xml_i="15143" xml_f="15157" txt_i="8286" txt_f="8300">460 (270–1380)</offsets></td><td align="left"><offsets xml_i="15179" xml_f="15193" txt_i="8301" txt_f="8315">810 (430–2020)</offsets></td><td align="left"><offsets xml_i="15215" xml_f="15228" txt_i="8316" txt_f="8329">490 (390–700)</offsets></td><td align="left"><offsets xml_i="15250" xml_f="15265" txt_i="8330" txt_f="8345">1420 (910–2120)</offsets></td><td align="left"><offsets xml_i="15287" xml_f="15291" txt_i="8346" txt_f="8350">0.17</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="15337" xml_f="15458" txt_i="8351" txt_f="8472">Median (interquartile range) are shown. A decrease in HOMA-S and ISI is indicative of a reduction in insulin sensitivity.</offsets></p><p><offsets xml_i="15465" xml_f="15546" txt_i="8473" txt_f="8554">* Changes in insulin sensitivity in this study have been previously reported [12]</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="15584" xml_f="15813" txt_i="8555" txt_f="8784">On logistic analysis, treatment (placebo vs. dexamethasone) was associated with change in insulin sensitivity, and remained after individual adjustment for age, and changes in BMI, blood pressure, and HDL cholesterol: β = -3.39, </offsets><italic><offsets xml_i="15821" xml_f="15823" txt_i="8784" txt_f="8786">P </offsets></italic><offsets xml_i="15832" xml_f="15869" txt_i="8786" txt_f="8820">&lt; 0.001 (as reported with HOMA-S [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="15901" xml_f="15903" txt_i="8820" txt_f="8822">12</offsets></xref><offsets xml_i="15910" xml_f="16331" txt_i="8822" txt_f="9243">]). Using partial correlation analysis (adjusting for treatment arm), associations between the change in each measured variable with changes in insulin sensitivity were investigated. Of variables analysed (including blood pressure, BMI and fasting metabolic indices: serum lipids, non-esterified fatty acids, TNF alpha, adiponectin, leptin, ghrelin), only systolic blood pressure (partial correlation coefficient: -0.50, </offsets><italic><offsets xml_i="16339" xml_f="16341" txt_i="9243" txt_f="9245">P </offsets></italic><offsets xml_i="16350" xml_f="16395" txt_i="9245" txt_f="9290">= 0.01) and diastolic blood pressure (-0.48, </offsets><italic><offsets xml_i="16403" xml_f="16405" txt_i="9290" txt_f="9292">P </offsets></italic><offsets xml_i="16414" xml_f="16458" txt_i="9292" txt_f="9336">= 0.02) were associated with HOMA-S and ISI.</offsets></p></sec><sec><title><offsets xml_i="16480" xml_f="16490" txt_i="9338" txt_f="9348">Discussion</offsets></title><p><offsets xml_i="16501" xml_f="16702" txt_i="9349" txt_f="9550">Contrary to our hypothesis, short-term dexamethasone treatment did not significantly change levels of TNF alpha, ghrelin, leptin or adiponectin, despite a treatment-related hyperinsulinaemic response [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="16734" xml_f="16736" txt_i="9550" txt_f="9552">12</offsets></xref><offsets xml_i="16743" xml_f="17091" txt_i="9552" txt_f="9900">]. The implication is that GC-mediated insulin resistance does not result from nor elicit major changes in these metabolically active hormones. Data here pertain only to insulin resistance associated with short-term exogenous glucocorticoid treatment, since other etiologies of insulin resistance may result from fundamentally different mechanisms.</offsets></p><p><offsets xml_i="17098" xml_f="17168" txt_i="9901" txt_f="9971">Dexamethasone-induced insulin resistance remains a complex mechanism [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="17200" xml_f="17202" txt_i="9971" txt_f="9973">15</offsets></xref><offsets xml_i="17209" xml_f="17319" txt_i="9973" txt_f="10083">] that is suggested to involve changes in whole body free fatty acid turnover, plasma insulin concentrations [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="17351" xml_f="17353" txt_i="10083" txt_f="10085">16</offsets></xref><offsets xml_i="17360" xml_f="17415" txt_i="10085" txt_f="10140">] and alterations in both insulin signal transduction [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="17447" xml_f="17449" txt_i="10140" txt_f="10142">17</offsets></xref><offsets xml_i="17456" xml_f="17484" txt_i="10142" txt_f="10170">] and glucose transporters [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="17516" xml_f="17518" txt_i="10170" txt_f="10172">18</offsets></xref><offsets xml_i="17525" xml_f="17684" txt_i="10172" txt_f="10331">] Both leptin and adiponectin promote catabolic energy generating processes, such as the mobilisation of triglycerides stores to promote fatty acid oxidation [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="17716" xml_f="17718" txt_i="10331" txt_f="10333">19</offsets></xref><offsets xml_i="17725" xml_f="17804" txt_i="10333" txt_f="10412">]. In line with our earlier report of a lack of effect on fasting NEFA levels [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="17836" xml_f="17838" txt_i="10412" txt_f="10414">12</offsets></xref><offsets xml_i="17845" xml_f="18037" txt_i="10414" txt_f="10606">], data here argue against a role of aberrant NEFA regulation as a mechanism of glucocorticoid-induced insulin resistance. Also, while whole body lipolysis is different between men and women [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="18069" xml_f="18071" txt_i="10606" txt_f="10608">20</offsets></xref><offsets xml_i="18078" xml_f="18154" txt_i="10608" txt_f="10684">] there is no gender variation in dexamethasone induced insulin resistance [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="18186" xml_f="18188" txt_i="10684" txt_f="10686">16</offsets></xref><offsets xml_i="18195" xml_f="18376" txt_i="10686" txt_f="10867">]. Hence, this disordered NEFA metabolism reported with dexamethasone-induced insulin resistance may be consequential of changes involving signal transduction and glucose transport.</offsets></p><p><offsets xml_i="18383" xml_f="18499" txt_i="10868" txt_f="10984">Circulating levels of TNF alpha show a coordinated increase with obesity during the course of gestational diabetes [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="18531" xml_f="18533" txt_i="10984" txt_f="10986">21</offsets></xref><offsets xml_i="18540" xml_f="18628" txt_i="10986" txt_f="11074">], and at a physiological level, this adipocytokine alters insulin signal transduction [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="18660" xml_f="18662" txt_i="11074" txt_f="11076">22</offsets></xref><offsets xml_i="18669" xml_f="18686" txt_i="11076" txt_f="11093">] and secretion [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="18718" xml_f="18720" txt_i="11093" txt_f="11095">23</offsets></xref><offsets xml_i="18727" xml_f="18995" txt_i="11095" txt_f="11363">]. Moreover, adiposity correlates with plasma levels of pro-inflammatory cytokines such as TNF alpha and the systemic acute phase protein C-reactive protein (CRP). In this study we have already reported that dexamethasone therapy resulted in a decrease in CRP levels [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="19027" xml_f="19029" txt_i="11363" txt_f="11365">12</offsets></xref><offsets xml_i="19036" xml_f="19219" txt_i="11365" txt_f="11548">]. Circulating CRP levels are suggested to relate to adipose derived mediators such as leptin and TNFα, and positively correlate with measures of obesity in otherwise healthy adults [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="19251" xml_f="19253" txt_i="11548" txt_f="11550">24</offsets></xref><offsets xml_i="19260" xml_f="19261" txt_i="11550" txt_f="11551">,</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="19293" xml_f="19295" txt_i="11551" txt_f="11553">25</offsets></xref><offsets xml_i="19302" xml_f="19458" txt_i="11553" txt_f="11709">]. In the present analysis we found no association between absolute levels or dexamethasone-related changes in CRP with metabolically active hormone levels.</offsets></p><p><offsets xml_i="19465" xml_f="19714" txt_i="11710" txt_f="11959">It is important to place our findings in the context of other studies examining the impact of glucocorticoids on metabolically active hormones and cytokines. Specifically, some human studies suggest that glucocorticoids may decrease ghrelin levels [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="19746" xml_f="19748" txt_i="11959" txt_f="11961">26</offsets></xref><offsets xml_i="19755" xml_f="19785" txt_i="11961" txt_f="11991">] and increase leptin levels [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="19817" xml_f="19819" txt_i="11991" txt_f="11993">27</offsets></xref><offsets xml_i="19826" xml_f="19947" txt_i="11993" txt_f="12114">]. However, one group reported that fasting obliterated the increase in leptin in response to exogenous glucocorticoids [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="19979" xml_f="19981" txt_i="12114" txt_f="12116">28</offsets></xref><offsets xml_i="19988" xml_f="20300" txt_i="12116" txt_f="12428">] which may account for the lack of a rise in leptin concentrations with glucocorticoid treatment in our subjects. In longer-term studies, the impact of glucocorticoids on metabolically active cytokines and hormones may be mediated by changes that accompany more chronic glucocorticoid effects, such as obesity [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="20332" xml_f="20334" txt_i="12428" txt_f="12430">29</offsets></xref><offsets xml_i="20341" xml_f="21125" txt_i="12430" txt_f="13214">], rather than by direct glucocorticoid effects. While it is conceivable that a larger sample size, longer treatment duration, or non-fasting blood assays might have generated positive findings, the highly significant change in insulin sensitivity we observed with dexamethasone reassures us that our study design allowed for detection of major alterations in metabolic cytokines and hormones. Furthermore, the since all subjects who received dexamethasone had undetectable post-treatment cortisol levels, we know that our negative findings were not a result of noncompliance with the intervention. Based on these factors, we suspect that any effects of short-term glucocorticoids on circulating levels of metabolic cytokines and adipokines are likely small, if indeed present at all.</offsets></p><p><offsets xml_i="21132" xml_f="21513" txt_i="13215" txt_f="13596">In summary, this randomised placebo-controlled study provides insight into the effects of glucocorticoids, without interference from pathological disease states that are commonly manifest amongst patients on GC therapy. Short-term dexamethasone therapy did not significantly change circulating concentrations of metabolically active hormones, despite increasing insulin resistance.</offsets></p></sec><sec><title><offsets xml_i="21535" xml_f="21554" txt_i="13598" txt_f="13617">Competing interests</offsets></title><p><offsets xml_i="21565" xml_f="21625" txt_i="13618" txt_f="13678">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="21647" xml_f="21669" txt_i="13680" txt_f="13702">Authors' contributions</offsets></title><p><offsets xml_i="21680" xml_f="22048" txt_i="13703" txt_f="14071">JVP, DEC and AVM carried out the hormone assays, and drafted the manuscript. DJB participated in the design of the study and assisted the statistical analysis (with JVP) and conceived of the study, GYHL, JPG, MG and SR also participated in the study design and its coordination/recruitment of subjects. EAH, DJB, JPG and SR contributed to the funding of this research.</offsets></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by the Cleveland Clinic Foundation Research Programs Council and the National Institutes of Health [R01 DK61516]</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schacke</surname><given-names>H</given-names></name><name><surname>Docke</surname><given-names>WD</given-names></name><name><surname>Asadullah</surname><given-names>K</given-names></name></person-group><article-title>Mechanisms involved in the side effects of Glucocorticoids</article-title><source>Pharmacol Ther</source><year>2002</year><volume>96</volume><fpage>23</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12441176</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reichardt</surname><given-names>HM</given-names></name><name><surname>Tuckermann</surname><given-names>JP</given-names></name><name><surname>Gottlicher</surname><given-names>M</given-names></name><name><surname>Vujic</surname><given-names>M</given-names></name><name><surname>Weih</surname><given-names>F</given-names></name><name><surname>Angel</surname><given-names>P</given-names></name><name><surname>Herrlich</surname><given-names>P</given-names></name><name><surname>Schutz</surname><given-names>G</given-names></name></person-group><article-title>Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor</article-title><source>EMBO J</source><year>2001</year><volume>24</volume><fpage>7168</fpage><lpage>7173</lpage><pub-id pub-id-type="pmid">11742993</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicod</surname><given-names>N</given-names></name><name><surname>Giusti</surname><given-names>V</given-names></name><name><surname>Besse</surname><given-names>C</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name></person-group><article-title>Metabolic adaptations to Dexamethasone-induced insulin resistance in healthy volunteers</article-title><source>Obes Res</source><year>2003</year><volume>11</volume><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">12740452</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pagano</surname><given-names>G</given-names></name><name><surname>Cavallo-Perin</surname><given-names>P</given-names></name><name><surname>Cassader</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects</article-title><source>J Clin Invest</source><year>1983</year><volume>72</volume><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">6355186</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asensio</surname><given-names>C</given-names></name><name><surname>Muzzin</surname><given-names>P</given-names></name><name><surname>Rohner-Jeanrenaud</surname><given-names>F</given-names></name></person-group><article-title>Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance</article-title><source>Int J Obes Relat Metab Disord</source><year>2004</year><volume>28</volume><fpage>S45</fpage><lpage>S52</lpage><pub-id pub-id-type="pmid">15592486</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>MacDonald</surname><given-names>TM</given-names></name><name><surname>Walker</surname><given-names>BR</given-names></name></person-group><article-title>Taking Glucocorticoids by prescription is associated with subsequent cardiovascular disease</article-title><source>Ann Inten Med</source><year>2004</year><volume>141</volume><fpage>764</fpage><lpage>770</lpage></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vendrell</surname><given-names>J</given-names></name><name><surname>Broch</surname><given-names>M</given-names></name><name><surname>Vilarrasa</surname><given-names>N</given-names></name><name><surname>Molina</surname><given-names>A</given-names></name><name><surname>Gomez</surname><given-names>JM</given-names></name><name><surname>Gutierrez</surname><given-names>C</given-names></name><name><surname>Simon</surname><given-names>I</given-names></name><name><surname>Soler</surname><given-names>J</given-names></name><name><surname>Richart</surname><given-names>C</given-names></name></person-group><article-title>Resistin, Adiponectin, Ghrelin, Leptin and proinflammatory cytokines: relationship to obesity</article-title><source>Obesity Research</source><year>2004</year><volume>12</volume><fpage>962</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">15229336</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Tumor necrosis factor alpha: a key component of the obesity-diabetes link</article-title><source>Diabetes</source><year>1994</year><volume>43</volume><fpage>1271</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7926300</pub-id></citation></ref><ref id="B9"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>DE</given-names></name><name><surname>Foster-Schubert</surname><given-names>KE</given-names></name><name><surname>Overduin</surname><given-names>J</given-names></name></person-group><article-title>Ghrelin and energy balance: Focus on current controversies</article-title><source>Curr Drug Targets</source><year>2005</year><comment></comment></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>RB</given-names></name></person-group><article-title>Leptin-much more than a satiety signal</article-title><source>Annu Rev Nutr</source><year>2000</year><volume>20</volume><fpage>45</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">10940326</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name></person-group><article-title>Adiponectin and metabolic syndrome</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2004</year><volume>24</volume><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">14551151</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brotman</surname><given-names>DJ</given-names></name><name><surname>Girod</surname><given-names>JP</given-names></name><name><surname>Garcia</surname><given-names>MJ</given-names></name><name><surname>Patel</surname><given-names>JV</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Posch</surname><given-names>A</given-names></name><name><surname>Saunders</surname><given-names>S</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Worley</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>S</given-names></name></person-group><article-title>Effects of short-term glucocorticoids on cardiovascular biomarkers</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>3202</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15769980</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name></person-group><article-title></article-title><source>Diabetelogia</source><year>1985</year><volume>28</volume><fpage>412</fpage><lpage>419</lpage></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McAuley</surname><given-names>KA</given-names></name><name><surname>Williams</surname><given-names>SM</given-names></name><name><surname>Mann</surname><given-names>JI</given-names></name><name><surname>Walker</surname><given-names>RJ</given-names></name><name><surname>Lewis-Barned</surname><given-names>NJ</given-names></name><name><surname>Temple</surname><given-names>LA</given-names></name><name><surname>Duncan</surname><given-names>AW</given-names></name></person-group><article-title>Diagnosing insulin resistance in the general population</article-title><source>Diabetes Care</source><year>2001</year><volume>24</volume><fpage>460</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">11289468</pub-id></citation></ref><ref id="B15"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Dinneen</surname><given-names>SF</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Draznin B, Rizza R</surname></name></person-group><article-title>The effects of glucocorticoid hormones on substrate metabolism</article-title><source>Clinical Research in Diabetes and Obesity</source><year>1997</year><publisher-name>Totowa, N.J.: Humana Press</publisher-name><fpage>243</fpage><lpage>58</lpage></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Binnert</surname><given-names>C</given-names></name><name><surname>Ruchat</surname><given-names>S</given-names></name><name><surname>Nicod</surname><given-names>N</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name></person-group><article-title>Dexamethasone-induced insulin resistance shows no gender difference in healthy humans</article-title><source>Diabetes Metab</source><year>2004</year><volume>30</volume><fpage>321</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15525874</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saad</surname><given-names>MJ</given-names></name><name><surname>Folli</surname><given-names>F</given-names></name><name><surname>Kahn</surname><given-names>CR</given-names></name></person-group><article-title>Insulin and dexamethasone regulate insulin receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in Fao hepatoma cells</article-title><source>Endocrinology</source><year>1995</year><volume>136</volume><fpage>1579</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">7895667</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakoda</surname><given-names>H</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name><name><surname>Anai</surname><given-names>M</given-names></name><name><surname>Funaki</surname><given-names>M</given-names></name><name><surname>Inukai</surname><given-names>K</given-names></name><name><surname>Katagiri</surname><given-names>H</given-names></name><name><surname>Fukushima</surname><given-names>Y</given-names></name><name><surname>Onishi</surname><given-names>Y</given-names></name><name><surname>Ono</surname><given-names>H</given-names></name><name><surname>Fujishiro</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>M</given-names></name><name><surname>Oka</surname><given-names>Y</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name></person-group><article-title>Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction</article-title><source>Diabetes</source><year>2000</year><volume>49</volume><fpage>1700</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11016454</pub-id></citation></ref><ref id="B19"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Hardie</surname><given-names>DG</given-names></name><name><surname>Hawley</surname><given-names>SA</given-names></name><name><surname>Scott</surname><given-names>JW</given-names></name></person-group><article-title>AMP-activated protein kinase – development of the energy sensor concept</article-title><source>J Physiol</source><year>2006</year><comment></comment></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Albu</surname><given-names>JB</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>O'Brien</surname><given-names>PC</given-names></name><name><surname>Jensen</surname><given-names>MD</given-names></name></person-group><article-title>Energy expenditure, sex, and endogenous fuel availability in humans</article-title><source>J Clin Invest</source><year>2003</year><volume>111</volume><fpage>981</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12671047</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>G</given-names></name><name><surname>Cseh</surname><given-names>K</given-names></name><name><surname>Baranyi</surname><given-names>E</given-names></name><name><surname>Melczer</surname><given-names>Z</given-names></name><name><surname>Speer</surname><given-names>G</given-names></name><name><surname>Hajos</surname><given-names>P</given-names></name><name><surname>Salamon</surname><given-names>F</given-names></name><name><surname>Turi</surname><given-names>Z</given-names></name><name><surname>Kovacs</surname><given-names>M</given-names></name><name><surname>Vargha</surname><given-names>P</given-names></name><name><surname>Karadi</surname><given-names>I</given-names></name></person-group><article-title>Tumor necrosis factor system in insulin resistance in gestational diabetes</article-title><source>Diabetes Research and Clinical Practice</source><year>2002</year><volume>56</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">11891016</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Budavari</surname><given-names>A</given-names></name><name><surname>Murray</surname><given-names>D</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha</article-title><source>J Clin Invest</source><year>1994</year><volume>94</volume><fpage>1543</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">7523453</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name></person-group><article-title>Tnf-alpha inhibits glucose-induced insulin secretion in a pancreatic beta-cell line (ins-1)</article-title><source>FEBS Lett</source><year>1995</year><volume>377</volume><fpage>237</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">8543058</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bullo</surname><given-names>M</given-names></name><name><surname>Garcia-Lorda</surname><given-names>P</given-names></name><name><surname>Megais</surname><given-names>I</given-names></name><name><surname>Salas-Salvado</surname><given-names>J</given-names></name></person-group><article-title>Systemic inflammation, adipose tissue tumour necrosis factor, and leptin expression</article-title><source>Obesity Research</source><year>2003</year><volume>11</volume><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">12690081</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mendall</surname><given-names>MA</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Asante</surname><given-names>M</given-names></name><name><surname>Ballam</surname><given-names>L</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Strachan</surname><given-names>DP</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name><etal></etal></person-group><article-title>Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease</article-title><source>Heart</source><year>1997</year><volume>78</volume><fpage>273</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">9391290</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>B</given-names></name><name><surname>Tschop</surname><given-names>M</given-names></name><name><surname>Heldwein</surname><given-names>W</given-names></name><name><surname>Pfeiffer</surname><given-names>AF</given-names></name><name><surname>Diederich</surname><given-names>S</given-names></name></person-group><article-title>Endogenous and exogenous glucocorticoids decrease plasma ghrelin in humans</article-title><source>Eur J Endocrinol</source><year>2004</year><volume>151</volume><fpage>113</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15248830</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>AM</given-names></name><name><surname>Tucker</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>DM</given-names></name><name><surname>Hughes</surname><given-names>IA</given-names></name><name><surname>Ahmed</surname><given-names>SF</given-names></name></person-group><article-title>Short-term effects of prednisolone and dexamethasone on circulating concentrations of leptin and sex hormone-binding globulin in children being treated for acute lymphoblastic leukaemia</article-title><source>Clin Endocrinol</source><year>2003</year><volume>58</volume><fpage>770</fpage><lpage>6</lpage></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dagogo-Jack</surname><given-names>S</given-names></name><name><surname>Umamaheswaran</surname><given-names>I</given-names></name><name><surname>Askari</surname><given-names>H</given-names></name><name><surname>Tykodi</surname><given-names>G</given-names></name></person-group><article-title>Leptin response to glucocorticoid occurs at physiological doses and is abolished by fasting</article-title><source>Obes Res</source><year>2003</year><volume>11</volume><fpage>232</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12582219</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Libe</surname><given-names>R</given-names></name><name><surname>Morpurgo</surname><given-names>PS</given-names></name><name><surname>Cappiello</surname><given-names>V</given-names></name><name><surname>Maffini</surname><given-names>A</given-names></name><name><surname>Bondioni</surname><given-names>S</given-names></name><name><surname>Locatelli</surname><given-names>M</given-names></name><name><surname>Zavanone</surname><given-names>M</given-names></name><name><surname>Beck-Peccoz</surname><given-names>P</given-names></name><name><surname>Spada</surname><given-names>A</given-names></name></person-group><article-title>Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery</article-title><source>Clin Endocrinol</source><year>2005</year><volume>62</volume><fpage>30</fpage><lpage>6</lpage></citation></ref></ref-list></back></article>